Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven G Terra

Showing results (11-20 of 59) with videos related to

Pageof 6
Sort By:
Diabetes, Obesity & Metabolism|January 8, 2019
Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trialSilvina Gallo, Bernard Charbonnel, Allison Goldman, et al.
The American Journal of Cardiology|August 6, 2008
Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitusSteven G Terra, Omar L Francone, Charles F Contant, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 7, 2020
Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled TrialsShrita Patel, Anne Hickman, Robert Frederich, et al.
Clinical Pharmacology in Drug Development|January 19, 2018
A Phase 1, Randomized, Placebo- and Active-Controlled Crossover Study to Determine the Effect of Single-Dose Ertugliflozin on QTc Interval in Healthy VolunteersVaishali Sahasrabudhe, Didier Saur, Kyle Matschke, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 26, 2019
A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
Vikas Kumar Dawra, Yali Liang, Haihong Shi, et al.
Clinical Therapeutics|September 19, 2018
Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic ImpairmentVaishali Sahasrabudhe, Steven G Terra, Anne Hickman, et al.
Journal of Clinical Pharmacology|April 23, 2004
Evaluation of methods for improving precision of blood pressure measurements in phase I clinical trialsSteven G Terra, Robert A Blum, Greg C Wei, et al.
Clinical Therapeutics|September 2, 2018
Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy SubjectsVikas K Dawra, Vaishali Sahasrabudhe, Yali Liang, et al.
Clinical and Translational Science|April 1, 2023
A multi-purpose Japanese phase I study in the global development of vupanorsen: Randomized, placebo-controlled, single-ascending dose study in adultsKei Fukuhara, Kenichi Furihata, Nobushige Matsuoka, et al.
Journal of Cardiac Failure|April 21, 2006
Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failureChristina L Aquilante, Steven G Terra, Richard S Schofield, et al.
Pageof 6

Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
Diabetes, Obesity & Metabolism|January 8, 2019
Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trialSilvina Gallo, Bernard Charbonnel, Allison Goldman, et al.
The American Journal of Cardiology|August 6, 2008
Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitusSteven G Terra, Omar L Francone, Charles F Contant, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 7, 2020
Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled TrialsShrita Patel, Anne Hickman, Robert Frederich, et al.
Clinical Pharmacology in Drug Development|January 19, 2018
A Phase 1, Randomized, Placebo- and Active-Controlled Crossover Study to Determine the Effect of Single-Dose Ertugliflozin on QTc Interval in Healthy VolunteersVaishali Sahasrabudhe, Didier Saur, Kyle Matschke, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 26, 2019
A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
Vikas Kumar Dawra, Yali Liang, Haihong Shi, et al.
Clinical Therapeutics|September 19, 2018
Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic ImpairmentVaishali Sahasrabudhe, Steven G Terra, Anne Hickman, et al.
Journal of Clinical Pharmacology|April 23, 2004
Evaluation of methods for improving precision of blood pressure measurements in phase I clinical trialsSteven G Terra, Robert A Blum, Greg C Wei, et al.
Clinical Therapeutics|September 2, 2018
Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy SubjectsVikas K Dawra, Vaishali Sahasrabudhe, Yali Liang, et al.
Clinical and Translational Science|April 1, 2023
A multi-purpose Japanese phase I study in the global development of vupanorsen: Randomized, placebo-controlled, single-ascending dose study in adultsKei Fukuhara, Kenichi Furihata, Nobushige Matsuoka, et al.
Journal of Cardiac Failure|April 21, 2006
Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failureChristina L Aquilante, Steven G Terra, Richard S Schofield, et al.
Pageof 6